Why the study?
Previous studies yielded conflicting data regarding the effects of SGLT2 inhibitors on ventricular arrhythmias in patients with heart failure.
Do SGLT2 inhibitors reduce major adverse arrhythmic cardiac events in patients with chronic heart failure evaluated with cardiac implantable electronic device monitoring?
Population
82 chronic heart failure patients undergoing continuous monitoring with a cardiac implantable electronic device
Comparison
Intra-patient difference before versus after SGLT2 inhibitor initiation
Design
Prospective observational study
Follow-up
Median 28 weeks (IQR 5)
Key result
In heart failure patients with a baseline arrhythmic phenotype, SGLT2 inhibitors significantly reduced non-sustained ventricular tachycardia (32% vs 68%, p=0.022) but not MAACE (28% vs 36%, p=0.727).
Authors
Loading...
SGLT2 inhibitors were not associated with lower MAACE; hypothesis-generating for NSVT reduction, warranting randomized confirmation before practice change.
Observational (n=82)
Do SGLT2 inhibitors reduce major adverse arrhythmic cardiac events in patients with chronic heart failure evaluated with cardiac implantable electronic device monitoring?
Absolute Event Rate: 28% vs 36%
p-value: p=0.727
SGLT2 inhibitors may have anti-arrhythmic properties, significantly reducing non-sustained ventricular tachycardia in heart failure patients with a pre-existing arrhythmic phenotype.
Basile et al. (2024) conducted an observational in chronic heart failure (n=82). SGLT2 inhibitors vs. Baseline (intra-patient comparison) was evaluated on Major adverse arrhythmic cardiac events (MAACE) in patients with an arrhythmic phenotype (p=0.727). In heart failure patients with a baseline arrhythmic phenotype, SGLT2 inhibitors significantly reduced non-sustained ventricular tachycardia (32% vs 68%, p=0.022) but not MAACE (28% vs 36%, p=0.727).